表柔比星分别联合碘油与Hepasphere载药微球对肝癌患者TACE的疗效分析

目的:研究表柔比星分别联合碘油与Hepasphere载药微球对经皮肝动脉化疗栓塞术(transcatheter arterial chemoembolization，TACE）治疗肝癌患者的疗效及预后分析。方法:选取病例被随机分为两组，分别注射表柔比星与碘油（A组）、表柔比星与Hepasphere微球混合液（B组）。1个月后对比术前及术后肝肾功、AFP，并采用mRECIST标准［疾病缓解率（CR+PR）、疾病控制率（CR+PR+SD）］对比两组之间差别。结果:A、B组患者术前、术后肝肾功等化验指标数值，组间和组内对比无统计学差异（P>0.05）；A、B组患者TACE治疗前AFP差异无统计学意义（P>0.05），术后AFP差异有统计学意义（P<0.05）；两组患者疾病缓解率、疾病控制率差异有统计学意义（P<0.05）。结论:表柔比星联合Hepasphere载药微球可以提高肝癌患者TACE的疗效。

Efficacy of epirubicin combined with lipiodol or Hepasphere loaded microspheres in the treatment of TACE in patients with hepatocellular carcinoma

Objective:To study the efficacy and prognosis of epirubicin combined with lipiodol or Hepasphere loaded microspheres in the treatment of hepatocellular carcinoma (HCC) in transcatheter arterial chemoembolization (TACE).Methods:The patients were randomly divided into two groups:Epirubicin and lipiodol (group A)，epirubicin and Hepasphere microspheres (group B)，respectively.After 1 month，the preoperative and postoperative liver and renal function，AFP，and mRECIST criteria including disease remission rate (CR+PR) and disease control rate (CR+PR+SD)，and the difference between the two groups were compared.Results:In the A and B group patients before and after operation,comparison of liver and kidney function tests index values between and within groups showed no significant difference (P>0.05).AFP before TACE in the two groups showed no significant difference (P>0.05)，and the difference was statistically significant after TACE (P<0.05).Remission rate，control rate of two groups of patients were statistically significant (P<0.05).Conclusion:Epirubicin combined with Hepasphere loaded microspheres can improve the efficacy of TACE in patients with hepatocellular carcinoma.